Found 590 matching trials
Immune Tumor Stroma Factors and Pathologic Complete Response After Neoadjuvant Chemotherapy in Early Breast Cancer
NAThis prospective cohort study aims to identify immune-related predictive fa...
Status
Active Not Recruiting
Location
Institute of Oncology Ljubljana
SIRT With Tremelimumab and Durvalumab for Resectable HCC
PHASE1The goal of this research study is to evaluate the safety and tolerability ...
Status
Active Not Recruiting
Location
Cedars-Sinai Medical Center
Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC
PHASE2This study compares the efficacy of neoadjuvant low-dose radiotherapy plus ...
Location
Multiple Locations
Neoadjuvant Pembrolizumab
PHASE2This multi-institutional, phase 2 clinical trial is studying two doses of p...
Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
PHASE3This is a Phase III, multicenter, open-label, randomized controlled trial. ...
Location
Henan Cancer Hospital
Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery
PHASE2This is a single-arm, single-center feasibility trial of patients with bord...
Location
Juravinski Hospital
Neoadjuvant Immunotherapy in Brain Metastases
PHASE2The purpose of this phase 2 study is to assess the feasibility and efficacy...
Location
Duke University Medical Center
Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)
PHASE2This is a multi-center, randomized, controlled open-label add-on design tri...
Location
UCSF Benioff Children's Hospital
Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced but Resecable Colon Cancer in the Elderly of 70 Years Old or More
PHASE3Colon cancer (CC) is the 5th most common cancer worldwide. Standard care fo...
Location
CHU Dijon Bourgogne
Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
PHASE3The purpose of this study is to compare a standard chemotherapy regimen of ...
Location
112 sites UK wide
Treatments Being Tested
Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimenInduction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimenInduction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimenInduction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimenInduction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimenConsolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimenMaintenance (intensive & non-intensive pathways) - lenalidomide maintenanceMaintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenanceHigh dose melphalan therapy and autologous stem cell transplant (intensive pathway only)